Skip to main content
. 2022 Nov 27;30(3):1914–1925. doi: 10.1245/s10434-022-12788-3

Table 2.

Factors affecting lung metastasis-free survival (LMFS) among osteosarcoma patients (N = 55)

N Lung metastasis-free survival (LMFS) Testa p value
Mean 95% CI), months 5-year LMFS 10-year LMFS
All patients 55 167.1 (146.5–187.7) 79.1% 79.1%
Sex
 Male 30 175.1 (49.0–201.2) 83.4% 83.4% 0.889 0.346
 Female 25 151.1 (121.2–180.9) 74.7% 74.7%
Age group (year)
  < 18 33 139.7 (115.3–164.1) 75.1% 75.1% 0.582 0.445
  ≥ 18 22 177.3 (149.4–205.2) 84.8% 84.8%
Length resected (cm)
  ≤ 15 31 178.9 (155.9–201.9) 86.2% 86.2% 1.313 0.252
  > 15 24 131.3 (100.2–162.5) 68.8% 68.8%
Cement used
 No 19 130.4 (109.9–150.9) 86.8% 86.8% 0.848 0.357
 Yes 36 160.6 (134.2–186.9) 75.4% 75.4%
Closure
 Uneventful 49 162.3 (139.4–185.2) 76.4% 76.4% 1.439 0.230
 Tight 6 149.0 100% 100%
Operative time (h)
  ≤ 4 33 191.5 (174.6–208.3) 92.9% 92.9% 8.297 0.004
  > 4 22 118.9 (85.2–152.8) 59.7% 59.7%
Chemotherapy
 No 3 157.0 100% 100% 0.752 0.386
 Yes 52 164.5 (142.7–186.4) 77.7% 77.7%
Tumor necrosis
  < 90% 16 156.3 (124.4–188.3) 84.4% 84.4% 0.284 0.594
  ≥ 90% 36 160.5 134.1–186.9) 75.3% 75.3%
Overall complications
 Absent 18 115.8 (89.8–141.8) 76.2% 76.2% 0.006 0.937
 Present 37 167.6 (143.3–191.9) 79.7% 79.7%
Type 1 complication
 Absent 51 167.3 (145.6–188.9) 79.2% 79.2% 0.065 0.799
 Present 4 99.5 (57.9–141.1) 75% 75%
Type 2 complication
 Absent 47 164.3 141.1–187.5) 77.4% 77.4% 0.234 0.629
 Present 8 172.3 (132.4–212.1) 87.5% 87.5%
Type 3 complication
 Absent 43 158.8 (136.8–180.8) 79.2% 79.2% 0.188 0.665
 Present 12 173.4 (135.0–211.8) 81.8% 81.8%
Type 4 complication
 Absent 41 158.4 (132.3–184.4) 74% 74% 1.512 0.219
 Present 14 147.0 (128.1–165.9) 92.9% 92.9%
Type 5 complication
 Absent 52 168.8 (148.0–189.6) 80% 80% 0.958 0.328
 Present 3 70.0 (30.0–110.0) 66.7% 66.7%

Bold value indicates significant at p < 0.05

Categorical variables were expressed as percentage; continuous variables were expressed as mean (95% CI)

aLog-rank test